The S&P 500 has advanced for the past three calendar years and continues to march higher in 2026, even reaching record levels. But this isn't without interruption, particularly in recent months. Investors have worried about the ongoing turmoil in Iran, higher oil prices, rising inflation in the U.S., and growing levels of spending in the artificial intelligence (AI) space. These concerns have weighed on the S&P 500 from time to time -- and could even potentially lead to longer-lasting declines.
So, what's an investor to do in such a situation? It's the perfect time to load up on dividend stocks, or companies that pay shareholders just for owning the stock. A dividend stock will offer you recurrent income regardless of the market's performance. This is great during any market environment, but it can be a real portfolio-saver during times of trouble. That's because these payments may at least partially compensate for weakness in some of your other investments. Even better, certain dividend players operate in areas -- such as healthcare -- that generate steady revenue even when times are tough.
Which dividend stocks to choose? The perfect place to start is with the list of Dividend Kings, companies that have lifted their dividend payments for at least the past 50 consecutive years. They are committed to dividend growth and have demonstrated that they have the resources to keep these payments going. With this in mind, let's check out two dividend stocks built to hold up when markets don't.
Image source: Getty Images.
1. Johnson & Johnson Johnson & Johnson (JNJ -0.75%) is a name you might know well, particularly for certain consumer health products. The company actually exited that business a couple of years ago and shifted the focus to its pharmaceutical and medtech units. This move, putting all resources into the highest-potential areas, proved to be a wise one as we can see through recent earnings reports.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
-0.75
%) $
-2.01
Current Price
$
267.11
J&J now has 28 products and platforms that bring in more than $1 billion in annual revenue. Its innovative medicines (pharma) business had eight brands growing in the double digits in the recent quarter, and J&J is on track toward its goal of becoming the No. 1 oncology company by 2030. The healthcare giant is also progressing toward another important goal: more than $100 billion in revenue this year. This would be the highest revenue level ever for J&J.
As for dividends, J&J pays $5.36 per share, representing a dividend yield of 1.9%. So, an investment in J&J brings you a winning healthcare business along with passive income in the form of a dividend that's been growing over time.
2. AbbVie AbbVie (ABBV +0.17%) is the company behind the world's first $20 billion drug, immunology blockbuster, Humira. That top-selling drug has since lost exclusivity, resulting in declines in sales, but AbbVie was prepared with newer immunology products, Skyrizi and Rinvoq, and these products are producing impressive results. In the recent quarter, Skyrizi and Rinvoq each delivered revenue growth of about 24% to more than $5 billion and $2 billion, respectively.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
0.17
%) $
0.43
Current Price
$
249.21
The company also has a leading aesthetics portfolio, with anti-wrinkle treatment Botox and filler Juvederm, as well as neuroscience and oncology portfolios. In the latest quarter, several of the company's neuroscience drugs delivered double-digit growth, including bipolar disorder treatment, Vraylar. That product generated more than $1 billion in revenue.
And total revenue continues to climb, even with the loss of Humira exclusivity, showing the strength of AbbVie's portfolio of commercialized drugs. In the quarter, worldwide revenue advanced 10% to more than $16 billion.
Like J&J, AbbVie has a long history of rewarding shareholders with dividends and lifting these payments year after year. This has brought the payment to $6.92, for a dividend yield of 2.7%, and makes AbbVie a stock built to hold up even when markets don't.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItAbbVie NYSE: ABBV executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit its long-term strategy.
Jeff Stewart, AbbVie’s executive vice president and chief commercial officer, said the company remains encouraged by the growth outlook for immunology markets including inflammatory bowel disease, atopic dermatitis and psoriatic arthritis. He said these markets are expanding as new therapies support earlier treatment and broader use across lines of therapy.
Get AbbVie alerts:
MarketBeat Week in Review – 08/03 - 08/07Stewart said SKYRIZI and RINVOQ, now in their eighth year of growth, continue to have opportunities for market-share gains. He pointed to planned or ongoing development in additional indications, including vitiligo, alopecia and hidradenitis suppurativa, or HS. AbbVie previously raised its long-term outlook for the vitiligo and alopecia opportunities to more than $3 billion, he said.
Immunology pipeline and Crohn’s disease plans In inflammatory bowel disease, Stewart said AbbVie expects approval of a subcutaneous induction regimen for SKYRIZI in Crohn’s disease during the fourth quarter. The company expects to release additional data from the AFFIRM study later in the quarter. He said topline findings showed strong endoscopic healing results and that the company views the regimen as a potential catalyst for its IBD position.
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad ExposureRoopal Thakkar, AbbVie’s executive vice president, head of research and chief scientific officer, discussed the company’s combination-therapy platform. In early data, a combination of SKYRIZI and AbbVie’s proprietary alpha-4 beta-7 therapy showed a doubling in endoscopic remission versus SKYRIZI monotherapy within the same study, according to Thakkar.
AbbVie plans to present additional data at gastrointestinal conferences later this year, representing about 80% of patient data, followed by a full dataset next year. The company is also enrolling a larger platform study evaluating SKYRIZI, its alpha-4 beta-7 therapy and an extended-duration TL1A therapy in Crohn’s disease and ulcerative colitis.
Thakkar said the company will evaluate whether higher dosing of the alpha-4 beta-7 treatment can further improve endoscopic outcomes. Stewart said transformational efficacy and convenient administration would be key commercial requirements for any combination product, including potentially using an on-body device or a simple injection.
AbbVie also expects data later this year from Phase III studies of lutikizumab and RINVOQ in HS. Thakkar said lutikizumab is being studied in patients who have not previously received biologics as well as patients who have failed them, while the RINVOQ study is enrolling patients who have failed biologic therapies. He said the trial designs accounted for potentially variable placebo responses in HS and included site training on lesion identification and counting.
Business development and investment priorities Scott Reents, AbbVie’s chief financial officer, said the company has completed roughly 30 transactions and spent about $20 billion over the past several years. About half of that amount related to the Apogee transaction, he said, while the remaining investments involved smaller and earlier-stage opportunities.
Reents said AbbVie has increased annual research and development spending by roughly $3.5 billion since 2022 and expects R&D spending to approach $10 billion this year. He said the company’s approach combines internal development with external innovation, particularly assets that complement existing franchises.
While AbbVie has the financial capacity to consider early-stage, late-stage and marketed assets, Reents said it does not need to pursue revenue simply for the sake of adding revenue. He said management will continue to evaluate opportunities in the company’s core therapeutic areas and adjacent categories through what he described as a measured and methodical process.
Reents reiterated AbbVie’s previously discussed high-single-digit compound annual revenue growth outlook through the decade and said the company’s first loss of exclusivity after its current major products is not expected until VRAYLAR in 2030.
Oncology and neuroscience developments In oncology, Thakkar highlighted AbbVie’s BCMA-directed T-cell engager etentamig for multiple myeloma. He said the therapy was designed with high affinity for BCMA and lower affinity for CD3, an approach intended to support efficacy while improving tolerability and convenience.
According to Thakkar, a study was stopped early at the request of the data monitoring committee after a median follow-up of 11 months. He said the results showed high response rates, progression-free survival and an overall-survival trend, with both hazard ratios below 0.5. The regimen involved one step-up dose and 13 injections annually because it is administered monthly.
AbbVie has dosed about 100 patients in outpatient settings across the development program, Thakkar said. The company plans discussions with regulators regarding labeling, including potential requirements for risk evaluation and mitigation and hospitalization. Stewart said AbbVie is preparing for a rapid filing and market entry.
Thakkar also described a solid-tumor pipeline including telisotuzumab vedotin, ABBV-901, ABBV-969, a KRAS program, DLL3-directed therapies and a partnership with RemeGen involving a PD-1/VEGF program. He said data from the PD-1/VEGF program were expected to be presented at the World Lung meeting.
In neuroscience, Thakkar said AbbVie is developing bretisilocin for major depressive disorder and plans another readout this year. He said early data showed deep and durable remission, while the treatment experience lasted about two hours. AbbVie is planning an acute Phase III study, a Phase II study to evaluate dose and durability, and a Phase II study in post-traumatic stress disorder.
Looking ahead, Thakkar said a successful year would include continued commercial execution in immunology, favorable HS results, advancement of oncology programs into Phase III, progress in psychiatry and rapid execution of atopic dermatitis studies involving zumilokibart from Apogee.
About AbbVie (NYSE:ABBV)AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.
AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in AbbVie Right Now?Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Pfizer (PFE -2.32%) has one of the highest dividend yields of any pharmaceutical stock -- 6.1% at its current share price. That's more than twice the yield that AbbVie (ABBV -3.00%) offers, but in the long run, I believe AbbVie is the better dividend stock.
Pfizer has slightly outperformed AbbVie this year, with a return of over 14% compared to more than 12% for AbbVie. However, in terms of revenue growth, AbbVie has grown by more than 138% over the past decade, while Pfizer's revenue is up just over 18% over that period.
Here are three more reasons why I prefer AbbVie as the better dividend stock.
Image source: Getty Images.
AbbVie has a better dividend track record Pfizer increased its quarterly dividend for 16 consecutive years, including a 2.3% raise last year to $0.43 per share. Its free-cash-flow (FCF) dividend payout ratio is around 89%, compared to just 65% for AbbVie.
AbbVie has an above-average dividend yield of about 2.66% at its current share price. The company has increased its quarterly dividend for 53 consecutive years, dating back to its time as a subsidiary of Abbott Laboratories. That makes AbbVie a Dividend King, a select group of stocks that have raised their dividend for 50 or more consecutive years. This year, AbbVie increased its quarterly dividend by 5.5% to $1.73.
But it's not just a stable dividend. Over the past decade, AbbVie has increased its dividend by more than 203%, compared to just 51% for Pfizer. If you count from 2013, the year that AbbVie became an independent company, it has increased its dividend by more than 330%.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
-3.00
%) $
-7.68
Current Price
$
248.78
AbbVie has already survived its big patent cliff AbbVie navigated the steep loss of exclusivity (LOE) on Humira by executing a precise, multi-year portfolio pivot long before biosimilars hit the U.S. market in 2023. Rather than relying on late-stage external acquisitions to patch the revenue hole, AbbVie developed two home-grown, next-generation immunology assets, Skyrizi and Rinvoq, designed specifically to capture market share across Humira's core indications in dermatology, rheumatology, and gastroenterology.
By 2025, combined annual sales for Skyrizi and Rinvoq surpassed $25 billion, effectively replacing the peak revenue lost from Humira and pushing total company revenue to record highs. Coupled with stable contributions from its neuroscience portfolio and aesthetics, AbbVie systematically bridged its immunology drop-off and returned to mid- to high-single-digit top-line growth without taking a permanent structural hit.
In the second quarter, the company reported sales of $16.9 billion, up 10.2% year over year, and earnings per share (EPS) of $2.03, an increase of 290% from the same period a year ago. Revenue growth was led by its immunology drugs, with Skyrizi bringing in $5.5 billion and Rinvoq $2.52 billion, while Humira's revenue was only $756 million.
In contrast, Pfizer will enter a multi-year LOE wave between 2026 and 2028, with roughly $17 billion to $18 billion in annual revenue exposed. Core blockbusters, including the anticoagulant Eliquis, oncology staples Ibrance and Xtandi, and key vaccine formulations, face generic entry, market erosion, and price negotiations under the Inflation Reduction Act. Pfizer's position is further complicated by the rapid normalization of its post-pandemic windfall from Comirnaty and Paxlovid.
Premium Feature
Moneyball Superscore
65/100
Today's Change
(
-2.32
%) $
-0.66
Current Price
$
27.79
AbbVie has a better debt position Both companies have been aggressive in acquisitions and are willing to spend money to gain new therapies. AbbVie is in the midst of a $10.9 billion deal to acquire Apogee Therapeutics, gaining access to that company's promising atopic dermatitis therapy, zumilokibart. Its biggest recent deal before that was its $10.1 billion buyout of ImmunoGen in 2024.
Pfizer spent $7 billion in 2025 to acquire Metsera, adding late-stage weight-loss therapies to its portfolio. Pfizer's last transformational mega-deal was its $43 billion acquisition of Seagen in December 2023, which expanded its oncology portfolio with antibody-drug conjugates.
AbbVie carries more long-term debt, roughly $62 billion as of the second quarter, compared to just $32.6 billion for Pfizer. However, Pfizer's debt-to-equity level is more than 3 times that of AbbVie's, whose leverage is supported by expanding post-Humira operational cash flows from Skyrizi and Rinvoq, providing strong coverage of debt service and dividend commitments. Pfizer is paying down its obligations as its core legacy blockbusters lose market exclusivity, putting greater near-term pressure on its cash-flow conversion and credit metrics.
All in all, AbbVie is the better stock for investors to go with today.
AbbVie (ABBV - Free Report) closed the most recent trading day at $248.78, moving -2.99% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.
The drugmaker's stock has climbed by 3.42% in the past month, exceeding the Medical sector's gain of 2.73% and the S&P 500's loss of 0.36%.
Analysts and investors alike will be keeping a close eye on the performance of AbbVie in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $3.86, reflecting a 107.53% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $17.36 billion, indicating a 10.02% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $14.05 per share and a revenue of $67.56 billion, demonstrating changes of +40.5% and +10.47%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for AbbVie. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.09% fall in the Zacks Consensus EPS estimate. As of now, AbbVie holds a Zacks Rank of #3 (Hold).
In the context of valuation, AbbVie is at present trading with a Forward P/E ratio of 18.25. This valuation marks a premium compared to its industry average Forward P/E of 17.92.
Investors should also note that ABBV has a PEG ratio of 1.16 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.27.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 102, this industry ranks in the top 42% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
Northwestern Mutual Wealth Management Co. lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 268,688 shares of the company’s stock after selling 3,842 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in AbbVie were worth $67,613,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. increased its stake in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares during the last quarter. Ieq Capital LLC increased its stake in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC raised its holdings in shares of AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after acquiring an additional 612,702 shares in the last quarter. 70.23% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades A number of brokerages have recently issued reports on ABBV. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. UBS Group raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Guggenheim lifted their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, BMO Capital Markets boosted their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $275.95.
View Our Latest Research Report on ABBV Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.
AbbVie Trading Down 0.1% NYSE ABBV opened at $256.27 on Tuesday. The firm has a market cap of $452.78 billion, a PE ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The stock has a 50-day moving average of $254.71 and a 200-day moving average of $230.21.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
GTS Securities LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 44.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,574 shares of the company’s stock after selling 2,819 shares during the period. GTS Securities LLC’s holdings in AbbVie were worth $899,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Burk Holdings LLC acquired a new stake in AbbVie during the second quarter worth approximately $30,000. IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the fourth quarter worth approximately $31,000. Finally, Abound Financial LLC bought a new position in AbbVie during the 4th quarter worth $32,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.
AbbVie Stock Performance Shares of ABBV opened at $256.27 on Tuesday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm has a market cap of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The business’s fifty day moving average is $254.71 and its 200-day moving average is $230.21. AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Announces Dividend The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is 195.48%.
Analyst Upgrades and Downgrades Several equities analysts have weighed in on the company. Evercore set a $235.00 price objective on AbbVie in a report on Friday, May 15th. Bank of America boosted their price target on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, Royal Bank Of Canada boosted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $275.95.
Check Out Our Latest Research Report on ABBV
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Flputnam Investment Management Co. trimmed its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 32.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 105,545 shares of the company’s stock after selling 50,825 shares during the quarter. Flputnam Investment Management Co.’s holdings in AbbVie were worth $26,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in the stock. Ranch Capital Advisors Inc. boosted its holdings in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in AbbVie during the second quarter valued at about $23,557,000. Wedge Capital Management L L P NC lifted its position in shares of AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP lifted its position in shares of AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after buying an additional 37,531 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth A number of research analysts have recently commented on the company. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company raised their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. UBS Group boosted their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Finally, Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.95. View Our Latest Stock Analysis on AbbVie
AbbVie Price Performance ABBV stock opened at $256.27 on Tuesday. The stock has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. The company has a 50-day moving average of $254.71 and a two-hundred day moving average of $230.21. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the company posted $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
New Mexico Educational Retirement Board increased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 87,955 shares of the company’s stock after acquiring an additional 6,700 shares during the period. AbbVie comprises about 0.6% of New Mexico Educational Retirement Board’s portfolio, making the stock its 24th biggest position. New Mexico Educational Retirement Board’s holdings in AbbVie were worth $22,133,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the fourth quarter worth about $28,000. Imprint Wealth LLC raised its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. Burk Holdings LLC acquired a new stake in AbbVie during the 2nd quarter worth approximately $30,000. IFC & Insurance Marketing Inc. acquired a new stake in AbbVie during the 4th quarter worth approximately $31,000. Finally, Abound Financial LLC bought a new stake in AbbVie during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Insiders Place Their Bets In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.
Analyst Ratings Changes Several equities analysts have issued reports on ABBV shares. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research report on Thursday, August 13th. Piper Sandler boosted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. BNP Paribas Exane increased their price objective on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Royal Bank Of Canada raised their target price on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Finally, JPMorgan Chase & Co. lifted their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $275.95. Get Our Latest Research Report on ABBV
AbbVie Stock Performance Shares of NYSE ABBV opened at $256.27 on Tuesday. The company has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company’s 50 day moving average price is $254.71 and its 200-day moving average price is $230.21.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.
AbbVie Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Meiji Yasuda Life Insurance Co decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 14.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,918 shares of the company’s stock after selling 3,258 shares during the quarter. AbbVie accounts for approximately 0.2% of Meiji Yasuda Life Insurance Co’s holdings, making the stock its 22nd largest holding. Meiji Yasuda Life Insurance Co’s holdings in AbbVie were worth $4,761,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ABBV. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC lifted its stake in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares in the last quarter. Burk Holdings LLC bought a new stake in AbbVie in the 2nd quarter valued at approximately $30,000. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter worth approximately $31,000. Finally, Abound Financial LLC acquired a new position in AbbVie during the 4th quarter worth approximately $32,000. 70.23% of the stock is currently owned by institutional investors.
Insider Buying and Selling at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.
Wall Street Analysts Forecast Growth ABBV has been the topic of a number of recent research reports. Citigroup lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. JPMorgan Chase & Co. raised their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Finally, Wells Fargo & Company boosted their price target on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $275.95. View Our Latest Stock Analysis on AbbVie
AbbVie Stock Performance Shares of NYSE:ABBV opened at $256.27 on Tuesday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. The company has a 50-day simple moving average of $254.71 and a 200 day simple moving average of $230.21.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.
AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Mufg Securities Americas Inc. grew its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,213 shares of the company’s stock after acquiring an additional 4,319 shares during the quarter. AbbVie accounts for 0.7% of Mufg Securities Americas Inc.’s holdings, making the stock its 24th biggest position. Mufg Securities Americas Inc.’s holdings in AbbVie were worth $13,391,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the business. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC grew its position in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its position in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC raised its stake in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after acquiring an additional 43 shares in the last quarter. Finally, Bank of Jackson Hole Trust lifted its position in AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after acquiring an additional 44 shares during the last quarter. 70.23% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In Several brokerages have weighed in on ABBV. Morgan Stanley restated an “overweight” rating and issued a $296.00 target price on shares of AbbVie in a research note on Monday, August 3rd. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Canaccord Genuity Group raised their price objective on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Guggenheim boosted their target price on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
Get Our Latest Stock Analysis on AbbVie Insider Buying and Selling In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.
AbbVie Trading Down 0.1% Shares of AbbVie stock opened at $256.27 on Tuesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The firm’s 50 day simple moving average is $254.71 and its two-hundred day simple moving average is $230.21.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s payout ratio is currently 195.48%.
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Cullinan Associates Inc. reduced its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,800 shares of the company’s stock after selling 4,655 shares during the period. AbbVie makes up approximately 1.3% of Cullinan Associates Inc.’s portfolio, making the stock its 20th largest position. Cullinan Associates Inc.’s holdings in AbbVie were worth $17,313,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC acquired a new position in AbbVie during the 4th quarter worth approximately $28,000. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. Burk Holdings LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at approximately $30,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie in the 4th quarter valued at approximately $31,000. Finally, Abound Financial LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Analyst Ratings Changes ABBV has been the topic of a number of recent analyst reports. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a report on Thursday, August 13th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. UBS Group upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Finally, Piper Sandler increased their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.95.
Read Our Latest Report on ABBV AbbVie Price Performance Shares of NYSE ABBV opened at $256.27 on Tuesday. The firm’s 50-day moving average is $254.71 and its two-hundred day moving average is $230.21. The company has a market capitalization of $452.78 billion, a PE ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the company posted $2.97 EPS. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.
Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Field & Main Bank purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,715 shares of the company’s stock, valued at approximately $2,696,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Prosperitas Financial LLC grew its holdings in AbbVie by 13.5% during the 2nd quarter. Prosperitas Financial LLC now owns 22,314 shares of the company’s stock valued at $5,615,000 after buying an additional 2,650 shares during the last quarter. Pin Oak Investment Advisors Inc. acquired a new stake in shares of AbbVie during the second quarter valued at $613,000. 49 Wealth Management LLC purchased a new stake in AbbVie during the 2nd quarter worth about $2,729,000. Livforsakringsbolaget Skandia Omsesidigt increased its position in AbbVie by 7.6% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 167,270 shares of the company’s stock worth $42,018,000 after purchasing an additional 11,800 shares in the last quarter. Finally, Rakuten Investment Management Inc. raised its stake in AbbVie by 10.2% in the 2nd quarter. Rakuten Investment Management Inc. now owns 289,091 shares of the company’s stock valued at $73,519,000 after purchasing an additional 26,793 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades A number of research analysts have issued reports on ABBV shares. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Bank of America upped their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Finally, Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $275.95.
Check Out Our Latest Analysis on AbbVie AbbVie Stock Down 0.1% NYSE:ABBV opened at $256.27 on Monday. The company has a market cap of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. The firm’s 50 day moving average is $254.66 and its two-hundred day moving average is $230.05. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Transactions at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Fulcrum Asset Management LLP purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 8,198 shares of the company’s stock, valued at approximately $2,085,000.
A number of other large investors have also recently bought and sold shares of the business. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the 4th quarter worth approximately $28,000. Imprint Wealth LLC increased its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares in the last quarter. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at $30,000. Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter worth $31,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.
Analyst Upgrades and Downgrades Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Bank of America increased their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Barclays raised their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. UBS Group boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, BNP Paribas Exane upped their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.95. Get Our Latest Stock Analysis on ABBV
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Price Performance Shares of NYSE ABBV opened at $256.27 on Monday. The company has a 50-day moving average price of $254.66 and a 200-day moving average price of $230.05. The stock has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the business posted $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Ferguson Wellman Capital Management Inc. increased its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 656,778 shares of the company’s stock after buying an additional 6,367 shares during the quarter. AbbVie comprises about 2.0% of Ferguson Wellman Capital Management Inc.’s portfolio, making the stock its 11th biggest position. Ferguson Wellman Capital Management Inc.’s holdings in AbbVie were worth $165,272,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Ranch Capital Advisors Inc. boosted its holdings in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in AbbVie in the 2nd quarter valued at approximately $23,557,000. Wedge Capital Management L L P NC raised its holdings in AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, Mission Wealth Management LP raised its holdings in AbbVie by 119.1% during the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after acquiring an additional 37,531 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.
AbbVie News Roundup Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Stock Performance AbbVie stock opened at $256.27 on Monday. The firm’s fifty day moving average price is $254.66 and its 200-day moving average price is $230.05. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a market cap of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current year.
AbbVie Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
Insider Activity In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.
Analyst Ratings Changes ABBV has been the topic of a number of recent research reports. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Piper Sandler increased their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a report on Thursday, August 13th. Finally, Morgan Stanley restated an “overweight” rating and set a $296.00 target price on shares of AbbVie in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
Read Our Latest Report on ABBV
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Braun Stacey Associates Inc. raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 87,528 shares of the company’s stock after purchasing an additional 3,269 shares during the quarter. Braun Stacey Associates Inc.’s holdings in AbbVie were worth $22,026,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the fourth quarter valued at about $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. Burk Holdings LLC acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $30,000. Legacy Wealth Managment LLC ID grew its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie during the fourth quarter worth approximately $31,000. Institutional investors own 70.23% of the company’s stock.
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Transactions at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock. Analysts Set New Price Targets A number of analysts have commented on ABBV shares. Bank of America lifted their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Wells Fargo & Company lifted their price objective on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Citigroup upped their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, UBS Group increased their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.
Read Our Latest Stock Report on ABBV
AbbVie Price Performance Shares of AbbVie stock opened at $256.27 on Monday. The firm has a market cap of $452.78 billion, a price-to-earnings ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29. The stock’s 50-day moving average is $254.66 and its 200-day moving average is $230.05. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
BNP Paribas lifted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 16.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,596 shares of the company’s stock after buying an additional 11,318 shares during the period. BNP Paribas’ holdings in AbbVie were worth $20,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently bought and sold shares of the stock. Norges Bank bought a new position in AbbVie in the 4th quarter worth $5,865,055,000. Corient Private Wealth LP bought a new position in shares of AbbVie during the 2nd quarter valued at approximately $559,736,000. Legal & General Group Plc purchased a new position in shares of AbbVie in the second quarter valued at $2,905,952,000. Wellington Management Group LLP increased its stake in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Finally, Capital World Investors boosted its stake in AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the period. 70.23% of the stock is owned by institutional investors.
AbbVie Trading Down 0.1% ABBV stock opened at $256.27 on Monday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The business’s 50-day moving average is $254.66 and its 200 day moving average is $230.05. The stock has a market cap of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year. AbbVie Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.
Analysts Set New Price Targets A number of analysts have weighed in on the company. Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Morgan Stanley reiterated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group boosted their price objective on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
View Our Latest Stock Report on AbbVie
AbbVie News Roundup Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Empowered Funds LLC reduced its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 202,359 shares of the company’s stock after selling 24,477 shares during the period. Empowered Funds LLC’s holdings in AbbVie were worth $50,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in shares of AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Ieq Capital LLC boosted its stake in AbbVie by 4.6% during the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its stake in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after purchasing an additional 612,702 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders. AbbVie Trading Down 0.1% ABBV opened at $256.27 on Monday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. The firm has a 50 day moving average of $254.66 and a two-hundred day moving average of $230.05.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 195.48%.
Wall Street Analyst Weigh In A number of equities analysts recently issued reports on ABBV shares. BMO Capital Markets boosted their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Bank of America upped their target price on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Citigroup upped their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Guggenheim increased their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target on the stock in a report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.95.
Check Out Our Latest Stock Report on AbbVie
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Dearborn Partners LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 128,402 shares of the company’s stock, valued at approximately $27,926,000. AbbVie comprises about 1.3% of Dearborn Partners LLC’s portfolio, making the stock its 23rd biggest position.
A number of other large investors also recently added to or reduced their stakes in the business. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Burk Holdings LLC acquired a new position in shares of AbbVie during the second quarter worth about $30,000. Legacy Wealth Managment LLC ID grew its stake in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie in the fourth quarter valued at $31,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades ABBV has been the topic of a number of recent analyst reports. BMO Capital Markets boosted their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Guggenheim increased their price objective on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Barclays boosted their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Wells Fargo & Company raised their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.95.
View Our Latest Analysis on AbbVie Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Trading Down 0.1% NYSE:ABBV opened at $256.27 on Monday. The stock has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The firm has a fifty day simple moving average of $254.66 and a two-hundred day simple moving average of $230.05. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is currently 195.48%.
Insiders Place Their Bets In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Glenview Trust Co purchased a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 421,257 shares of the company’s stock, valued at approximately $91,619,000.
A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. Ranch Capital Advisors Inc. lifted its stake in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of AbbVie by 11.2% in the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after acquiring an additional 45,132 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of AbbVie in the second quarter valued at approximately $23,557,000. Wedge Capital Management L L P NC grew its position in shares of AbbVie by 7.5% during the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after acquiring an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP grew its position in shares of AbbVie by 119.1% during the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after acquiring an additional 37,531 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Trading Down 0.1% Shares of ABBV opened at $256.27 on Monday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The firm has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29. The firm’s 50-day moving average is $254.66 and its two-hundred day moving average is $230.05. AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business earned $2.97 earnings per share. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.
Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.
Analysts Set New Price Targets A number of analysts recently weighed in on ABBV shares. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. Guggenheim boosted their price target on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company boosted their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.95.
Get Our Latest Report on AbbVie
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More Five stocks we like better than AbbVie AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AFT Forsyth & Company Inc. purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,023 shares of the company’s stock, valued at approximately $1,516,000. AbbVie makes up about 0.7% of AFT Forsyth & Company Inc.’s portfolio, making the stock its 25th biggest holding.
Other large investors have also recently modified their holdings of the company. ACT Advisors LLC. grew its stake in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC increased its position in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after purchasing an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC lifted its position in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC boosted its stake in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after purchasing an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC raised its stake in AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock worth $751,000 after buying an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie Trading Down 1.5% NYSE:ABBV opened at $256.27 on Friday. The company has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The business’s 50-day moving average is $254.66 and its 200 day moving average is $230.06.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the prior year, the firm earned $2.97 earnings per share. AbbVie’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year. AbbVie Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is currently 195.48%.
More AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.
Analysts Set New Price Targets Several research analysts recently issued reports on the stock. Canaccord Genuity Group increased their price target on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Bank of America raised their target price on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Finally, Cantor Fitzgerald lifted their target price on shares of AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $275.95.
View Our Latest Stock Analysis on ABBV
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Legal & General Group Plc acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,548,053 shares of the company’s stock, valued at approximately $2,905,952,000. AbbVie accounts for about 0.6% of Legal & General Group Plc’s investment portfolio, making the stock its 23rd biggest holding. Legal & General Group Plc owned approximately 0.65% of AbbVie at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. The Manufacturers Life Insurance Company bought a new stake in shares of AbbVie during the 2nd quarter valued at about $655,268,000. Kelly Lawrence W & Associates Inc. CA bought a new position in AbbVie in the second quarter worth about $1,961,000. Jones Financial Companies Lllp bought a new position in AbbVie in the second quarter worth about $3,790,000. Trajan Wealth LLC purchased a new stake in AbbVie in the second quarter worth about $9,448,000. Finally, Van Hulzen Asset Management LLC bought a new stake in AbbVie during the 2nd quarter valued at approximately $11,398,000. 70.23% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In ABBV has been the topic of a number of research analyst reports. Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Barclays lifted their price target on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald upped their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.95.
Read Our Latest Stock Analysis on ABBV AbbVie News Roundup Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Activity In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.
AbbVie Stock Down 1.5% Shares of ABBV opened at $256.27 on Friday. The stock has a market cap of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29. The business’s 50 day moving average price is $254.66 and its 200-day moving average price is $230.06. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Kelly Lawrence W & Associates Inc. CA bought a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,791 shares of the company’s stock, valued at approximately $1,961,000.
Several other hedge funds have also modified their holdings of ABBV. Norges Bank acquired a new stake in shares of AbbVie during the fourth quarter valued at about $5,865,055,000. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Capital World Investors grew its position in shares of AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after buying an additional 6,736,161 shares in the last quarter. Cardano Risk Management B.V. increased its stake in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades ABBV has been the subject of a number of research reports. Bank of America lifted their price target on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Wells Fargo & Company increased their target price on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.95.
Check Out Our Latest Report on AbbVie Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.
AbbVie Stock Down 1.5% Shares of ABBV opened at $256.27 on Friday. The firm has a market capitalization of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29. The firm has a 50-day moving average price of $254.66 and a 200 day moving average price of $230.06. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter last year, the business earned $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is 195.48%.
More AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Kinloch Capital LLC acquired a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 25,696 shares of the company’s stock, valued at approximately $6,466,000. AbbVie accounts for approximately 2.4% of Kinloch Capital LLC’s holdings, making the stock its 3rd biggest holding.
Other hedge funds also recently made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC raised its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Burk Holdings LLC bought a new stake in AbbVie in the second quarter worth about $30,000. Legacy Wealth Managment LLC ID boosted its position in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the fourth quarter valued at approximately $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is owned by insiders.
Key AbbVie News Here are the key news stories impacting AbbVie this week: Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Stock Performance NYSE ABBV opened at $256.27 on Friday. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The company has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The company’s 50-day simple moving average is $254.66 and its two-hundred day simple moving average is $230.06.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.
Wall Street Analyst Weigh In ABBV has been the subject of several research analyst reports. Piper Sandler lifted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. BNP Paribas Exane raised their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Guggenheim boosted their price objective on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Barclays lifted their price target on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $275.95.
Get Our Latest Stock Report on AbbVie
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Cooper Haims Advisors LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,828 shares of the company’s stock, valued at approximately $712,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Burk Holdings LLC purchased a new position in AbbVie in the 2nd quarter worth $30,000. Litman Gregory Wealth Management LLC purchased a new stake in AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC increased its holdings in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie in the fourth quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Stock Performance AbbVie stock opened at $256.27 on Friday. The stock has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29. The company’s fifty day moving average price is $254.66 and its 200 day moving average price is $230.06. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm posted $2.97 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts predict that AbbVie Inc. will post 14.05 EPS for the current year. AbbVie Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
Insider Transactions at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.
Analysts Set New Price Targets ABBV has been the topic of several research reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research report on Thursday, August 13th. Finally, Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $275.95.
View Our Latest Stock Report on AbbVie
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
EFG International AG acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 71,881 shares of the company’s stock, valued at approximately $18,086,000.
Other large investors also recently bought and sold shares of the company. State Street Corp boosted its position in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC lifted its stake in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. Bank of America Corp DE boosted its holdings in shares of AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after acquiring an additional 356,394 shares during the last quarter. Norges Bank acquired a new stake in shares of AbbVie in the fourth quarter worth $5,865,055,000. Finally, Capital Research Global Investors increased its stake in shares of AbbVie by 0.7% in the fourth quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after acquiring an additional 177,370 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. Insider Transactions at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders. AbbVie Stock Down 1.5% Shares of AbbVie stock opened at $256.27 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The business has a 50-day moving average price of $254.66 and a 200 day moving average price of $230.06. The firm has a market cap of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period last year, the company earned $2.97 earnings per share. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is currently 195.48%.
Analysts Set New Price Targets Several research firms have commented on ABBV. Citigroup upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. upped their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 target price on shares of AbbVie in a report on Monday, August 3rd. Wells Fargo & Company boosted their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Finally, Piper Sandler upped their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
Check Out Our Latest Report on ABBV
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Jupiter Topco LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,201,973 shares of the company’s stock, valued at approximately $1,560,354,000. Jupiter Topco LLC owned 0.35% of AbbVie as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in ABBV. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. Burk Holdings LLC purchased a new stake in AbbVie in the second quarter valued at about $30,000. Legacy Wealth Managment LLC ID raised its stake in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in AbbVie in the fourth quarter worth about $31,000. Institutional investors own 70.23% of the company’s stock.
Analysts Set New Price Targets Several equities analysts recently issued reports on the company. Wells Fargo & Company upped their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. JPMorgan Chase & Co. increased their price target on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Evercore set a $235.00 price target on shares of AbbVie in a report on Friday, May 15th. HSBC reaffirmed a “buy” rating and set a $300.00 target price on shares of AbbVie in a research note on Monday, July 6th. Finally, Canaccord Genuity Group boosted their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $275.95.
View Our Latest Report on ABBV Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case. Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth. AbbVie Trading Down 1.5% ABBV stock opened at $256.27 on Friday. The company has a market capitalization of $452.78 billion, a PE ratio of 72.39, a P/E/G ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The business’s fifty day moving average price is $254.66 and its 200 day moving average price is $230.06.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is 195.48%.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles Five stocks we like better than AbbVie Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (ABBV -1.44%) and Pfizer Inc (PFE -1.25%) as they navigate drug pricing reforms and evolving pipelines.
AbbVie has successfully diversified its portfolio beyond its historic blockbuster Humira, while Pfizer is aggressively deploying capital from its pandemic-era windfall into new oncology and obesity treatments. Both companies are cornerstones of many income-focused portfolios, yet they offer distinct risk profiles for those seeking healthcare exposure.
The case for AbbVieAccording to its latest annual report, AbbVie focuses on high-growth therapeutic areas like immunology, neuroscience, and aesthetics within the pharmaceutical stocks universe. Its recent growth is driven largely by two key immunology drugs which together represented nearly 42% of its revenue in 2025. The company distributes its products through major wholesalers including McKesson Corp (MCK -1.45%), Cardinal Health Inc (CAH -0.57%), and Cencora Inc (COR -1.86%). Customer concentration like this adds a layer of risk to the business.
In FY 2025, revenue reached nearly $61.2 billion, representing an increase of approximately 9% compared to the prior year. This growth is notable as the company successfully offset the declining sales of its former top-selling drug Humira. Net income for the period was roughly $4.2 billion, which is a slight decrease from the previous year. Still, this performance shows the ability to maintain top-line growth even as older products face competitive pressure.
As of its December 2025 balance sheet, the debt-to-equity ratio is -21.1x, which means total liabilities exceed shareholder equity. The so-called current ratio is roughly 0.7x, a metric that measures a company's ability to cover its short-term obligations with its short-term assets. Free cash flow, which is cash from operations minus capital expenditures, was approximately $17.8 billion for the fiscal year.
The case for PfizerPfizer applies its global resources to develop and manufacture a wide range of vaccines and medicines for patients in roughly 200 countries. In its latest annual report, Pfizer details how it applies its scientific resources to develop a wide array of medicines and vaccines for global distribution, including how the company is currently focused on expanding its oncology pipeline through significant acquisitions such as Seagen. It also relies on key products like Eliquis, which accounted for approximately 13% of its total revenue in 2025.
In FY 2025, revenue reached nearly $62.6 billion, a decline of roughly 1.6% from the previous year. This slight contraction reflects the ongoing normalization of its business after the height of the pandemic. Net income for the year was approximately $7.8 billion, a substantial increase compared to the results reported two years prior.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x. This ratio shows the proportion of debt a company uses relative to the equity provided by its shareholders, offering insight into its financial leverage. The current ratio is roughly 1.2x, and free cash flow for the year reached nearly $9.1 billion, supporting its ongoing dividend payments and internal research initiatives.
Risk profile comparisonAbbVie faces intense pressure from the loss of patent protection for its key products as biosimilars enter the market. The Inflation Reduction Act also introduces risks by allowing the government to set prices for several of its high-expenditure drugs, including Botox and Vraylar. Furthermore, the company relies on complex international supply chains where any disruption or failure to meet regulatory standards could result in product shortages.
Pfizer is navigating a period of significant patent expirations that could reduce revenue between 2026 and 2030. It is also subject to ongoing legal proceedings, including product liability claims and patent disputes, which may result in financial settlements or loss of exclusivity. Failure to successfully launch new products from its research and development pipeline could also impact its future financial results and valuation.
Valuation comparisonPfizer appears to be the more value-oriented option based on its lower Forward P/E, while AbbVie carries a higher P/S ratio following its recent growth.
MetricAbbViePfizerForward P/E16.1x9.8xP/S ratio7.2x2.6xValuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
AbbVie is buying itself growth with its recent deal to acquire Apogee Therapeutics (APGE -0.01%). Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.
AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.
Pfizer has been in an odd spot in recent years, as the boost it got from its COVID-19 vaccines is wearing off, with fewer people getting them and competitors proliferating. Wall Street has also been concerned about a "wall" of patent expirations facing the business in the next few years.
But there is reason for hope. Pfizer has made great strides in bringing its own GLP-1s to market. In December, it struck a deal with a Chinese pharmaceutical company to develop small-molecule GLP-1s that will lead to a daily pill. Plus its recent acquisitions have driven overall growth for the company.
For fiscal 2026, net income is seen jumping by some 40% to more than $11 billion, with sales increasing by a smaller margin to $61.7 billion. Sales beyond are expected to decline due to expiring patents, but the company is expecting three FDA decisions and multiple trial readouts and starts that should generate at least some new products to power the business.
AbbVie is in excellent shape, but Pfizer appears to be a value play for those willing to hold onto shares through a period of seeing new drugs come to market. With its lower P/S and forward P/E rations, Pfizer is the choice for long-term investors.
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
AbbVie (NYSE:ABBV | ABBV Price Prediction) investors just banked another $1.73 per share, the third payment at that level after the board pushed the quarterly rate up 5.5% from the prior $1.64. The check landed on August 14, 2026, and it arrived against a backdrop most dividend investors have been dreading for years: the Humira patent cliff has arrived and is showing up in the income statement every quarter.
Yet the payout keeps climbing. That tension, an eroding legacy franchise funding a rising distribution, is what a scorecard needs to grade.
The Payout Math: A B+ Coverage Story AbbVie generated $19.03 billion in operating cash flow in fiscal 2025 against $1.21 billion in capex, leaving roughly $17.8 billion in free cash flow. The dividend cost the company $11.66 billion over the same period, up from $11.03 billion in 2024 and $10.54 billion in 2023. That works out to a free-cash-flow payout ratio in the mid 60s, which is why the stock still carries a 3.88% free cash flow yield even after the recent run.
Trailing net income of $4.23 billion in 2025 sits well below the cash dividend, which is why the reported P/E of 108 and earnings yield of 0.92% flash red on a screener. Amortization of acquired intangibles from the Allergan deal, plus IPR&D charges, is doing most of that damage. On an adjusted basis, management guided full-year 2026 EPS to $13.87 to $14.07, which comfortably covers the roughly $6.92 in annualized dividends.
The Growth Streak: An A Grade Nobody Disputes AbbVie inherited Abbott’s aristocrat streak at the 2013 spinoff, and the combined record now runs past 50 consecutive years, the kind of pedigree we screened for in a free Dividend Kings report. The quarterly payout has moved from $0.40 in 2013 to $1.73 today, a run that includes double-digit raises through the Humira peak years and mid-single-digit increases through the biosimilar transition. The latest 5.5% bump tells you management is signaling confidence, but also pacing itself.
The Patent Cliff: Where the C Grade Lives Humira is ultimately the reason for this scorecard’s asterisk. Global sales fell to $756 million in the second quarter of 2026, an operational decline of 36.1%. That comes on top of a roughly 49.5% drop in fiscal 2025. Imbruvica added insult, falling 29.4% under IRA pricing and share pressure.
Separately, Skyrizi delivered $5.5 billion in Q2 sales at 24% growth, Rinvoq crossed $2.5 billion at 23.7%, and neuroscience revenue topped $3.2 billion. Total revenue reached nearly $17 billion at 10.2% reported growth, and management raised full-year revenue guidance to approximately $67.6 billion.
Here’s the catch: Skyrizi’s own composition-of-matter patent expires in 2033. CEO Rob Michael pointed to later-expiring IP in the mid-2030s and later and said the company does “not expect to see biosimilar application filings until the end of this decade.” Investors are being asked to trust that history does not repeat.
Leverage and the Apogee Question AbbVie carries negative shareholders’ equity, a legacy of the Allergan acquisition, and 2025 interest expense hit $2.89 billion. The pending $10.9 billion Apogee Therapeutics acquisition will add roughly $200 million in annual net interest expense and a 14-cent dilutive hit to 2026 adjusted EPS. Management committed to a net leverage target of two times within two to three years after close.
Final Grade: B At $261.72 and a 2.54% yield, ABBV has already delivered a 27.32% total-return year and 181.91% over five years, so the market is grading the transition kindly. The dividend earns a solid B: cash coverage is intact, the growth streak is genuine, and Skyrizi plus Rinvoq are pulling their weight. Points come off for the leverage profile, the mid-single-digit raise pace, and the fact that this same story will need to be told again in a decade when Skyrizi’s own exclusivity fades. Investors buying today are paying a fair price for a payout that works, provided the pipeline keeps delivering.
Contact [email protected] for any questions or corrections.
Key Takeaways AbbVie's Phase III CERVINO study evaluated etentamig in triple-class exposed RRMM patients.AbbVie's etentamig improved ORR to 74% versus 45.7% for standard available therapies.Etentamig cut the risk of disease progression or death by 60%, with a 0.40 PFS hazard ratio. AbbVie (ABBV - Free Report) reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatment with three major drug classes.
The study is investigating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) for treating patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) RRMM.
The CERVINO study met both of its primary goals, showing that treatment with etentamig significantly improved the objective response rate (ORR) and progression-free survival (PFS) compared with standard available therapies.
Year to date, shares of AbbVie have risen 16.6% compared with the industry’s growth of 17.6%.
Image Source: Zacks Investment Research
More on AbbVie’s Phase III CERVINO Study DataData from the study showed that treatment with etentamig led to an ORR of 74% compared with 45.7% for SAT. It also reduced the risk of disease progression or death by 60%, with a PFS hazard ratio of 0.40. The PFS benefit was seen across all prespecified patient subgroups.
At 12 months, the overall survival rate was 87.9% for patients who were treated with etentamig compared with 72% for those receiving SAT. However, AbbVie noted that the prespecified statistical boundary for overall survival had not been crossed at the data cutoff date.
Etentamig also showed a manageable safety profile when given after a single step-up dose followed by monthly dosing. It also demonstrated low rates of cytokine release syndrome and fatal infections in the given patient population.
At the data cutoff, the CERVINO study included 393 patients who had received a median of three prior treatments. After a median follow-up of 11.4 months, treatment with etentamig showed statistically significant and clinically meaningful efficacy, while also demonstrating a manageable safety profile.
Per management, the results support the potential of etentamig, a BCMA-directed T-cell engager, to offer a convenient treatment option that could potentially be administered in outpatient and community-based settings.
AbbVie plans to discuss the results from the CERVINO study with regulatory authorities worldwide to decide the next steps of development for etentamig. The company also plans to present the data at a medical conference later this month.
ABBV Completes Acquisition of ApogeeIn a separate press release, AbbVie announced that it has completed the previously announced acquisition of Apogee Therapeutics for approximately $10.9 billion.
The acquisition further strengthens AbbVie's dominant immunology pipeline by adding promising dermatology, respiratory and inflammatory disease assets supporting long-term growth.
ABBV’s Zacks Rank & Stocks to ConsiderAbbVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) , Anika Therapeutics (ANIK - Free Report) and Precigen (PGEN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 3.5% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Anika Therapeutics’ 2026 bottom line have moved from a loss of 12 cents per share to earnings of $1.05 per share, while estimates for 2027 have increased from 16 cents to 95 cents during the same time. ANIK’s shares have surged 118.6% year to date.
Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have moved from a loss of 2 cents per share to earnings of 25 cents, while estimates for 2027 have increased from 25 cents to 86 cents during the same time. PGEN’s shares have rallied 70.9% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 108.96%.
Jones Financial Companies Lllp acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,061 shares of the company’s stock, valued at approximately $3,790,000.
Other institutional investors have also modified their holdings of the company. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the 4th quarter worth $28,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Burk Holdings LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth $30,000. Legacy Wealth Managment LLC ID lifted its stake in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Insider Activity In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.
AbbVie Trading Down 0.4% ABBV opened at $260.69 on Friday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The firm has a market cap of $460.58 billion, a price-to-earnings ratio of 73.64, a PEG ratio of 1.18 and a beta of 0.29. The company has a fifty day simple moving average of $254.57 and a 200 day simple moving average of $229.87. AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business posted $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.
Analyst Ratings Changes A number of equities research analysts recently weighed in on ABBV shares. BNP Paribas Exane upped their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Barclays upped their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Citigroup raised their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Cantor Fitzgerald boosted their price target on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95.
View Our Latest Analysis on AbbVie
AbbVie News Roundup Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction. Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading Five stocks we like better than AbbVie The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Aberdeen Wealth Management LLC bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,276 shares of the company’s stock, valued at approximately $2,334,000. AbbVie makes up approximately 1.1% of Aberdeen Wealth Management LLC’s investment portfolio, making the stock its 14th biggest position.
A number of other institutional investors have also modified their holdings of the company. Visionary Wealth Advisors purchased a new stake in shares of AbbVie during the second quarter worth about $14,980,000. Cullen Capital Management LLC purchased a new position in shares of AbbVie in the second quarter worth $1,800,000. Whalen Wealth Management Inc. purchased a new position in shares of AbbVie in the second quarter worth $931,000. Dearborn Partners LLC acquired a new stake in shares of AbbVie during the second quarter worth $27,926,000. Finally, Trail Ridge Investment Advisors LLC acquired a new stake in shares of AbbVie during the second quarter worth $525,000. 70.23% of the stock is currently owned by institutional investors.
AbbVie Price Performance NYSE ABBV opened at $260.69 on Friday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The company has a market capitalization of $460.58 billion, a PE ratio of 73.64, a P/E/G ratio of 1.18 and a beta of 0.29. The company has a fifty day moving average of $254.57 and a 200 day moving average of $229.87.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year. AbbVie Announces Dividend The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.
Analyst Ratings Changes Several research firms recently issued reports on ABBV. Piper Sandler upped their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Guggenheim lifted their price target on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. increased their price objective on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Royal Bank Of Canada raised their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
Get Our Latest Report on AbbVie
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction. Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Brandywine Trust Co. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 100,852 shares of the company’s stock, valued at approximately $25,378,000. AbbVie comprises about 4.1% of Brandywine Trust Co.’s investment portfolio, making the stock its 4th biggest position.
Other institutional investors have also added to or reduced their stakes in the company. Ranch Capital Advisors Inc. boosted its position in shares of AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after buying an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its position in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in AbbVie during the 2nd quarter valued at $23,557,000. Wedge Capital Management L L P NC lifted its stake in AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares in the last quarter. Finally, Mission Wealth Management LP boosted its holdings in AbbVie by 119.1% during the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after acquiring an additional 37,531 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth Several analysts have recently commented on ABBV shares. Bank of America increased their target price on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. Morgan Stanley reiterated an “overweight” rating and issued a $296.00 price objective on shares of AbbVie in a research note on Monday, August 3rd. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Wells Fargo & Company upped their target price on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $275.95.
Check Out Our Latest Report on AbbVie AbbVie Trading Down 0.4% Shares of NYSE ABBV opened at $260.69 on Friday. The stock has a fifty day simple moving average of $254.57 and a two-hundred day simple moving average of $229.87. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The firm has a market cap of $460.58 billion, a price-to-earnings ratio of 73.64, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the business posted $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio is 195.48%.
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction. Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis Insider Buying and Selling In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by company insiders.
About AbbVie (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
See Also Five stocks we like better than AbbVie The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now Dropping the Dough: Yum! Brands Strategically Trims the Fat These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AbbVie remains a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in immunology, oncology, neuroscience, and aesthetics, with only modest near-term EPS dilution. Q2 results beat expectations, driven by Skyrizi and Rinvoq, while technicals and momentum favor continued upside toward a $292 price target.
Etentamig beat standard treatment by 28.3 percentage points and met the Phase 3 study's progression-free-survival goal. Summary
AbbVie’s oncology revenue fell 1.5% as Imbruvica sales dropped 29.4%.
AbbVie ABBV, the pharmaceutical and biotechnology giant, put its cancer pipeline squarely on investors' radar Thursday, with shares priced at $260.445. Etentamig produced a 74% overall response rate in a pivotal blood-cancer trial. Standard treatments managed 45.7%. That is a massive 28.3-percentage-point advantage—and exactly the kind of clinical gap that can reshape an oncology franchise.
The Phase 3 study also cleared its progression-free-survival target in patients with relapsed or refractory multiple myeloma. The efficacy signal looks powerful. The investment case is not finished. Etentamig remains investigational, regulators have not reviewed the complete findings, and the market still needs detailed answers on safety, response durability and approval timing.
AbbVie needs this win. Its second-quarter results showed oncology revenue slipping 1.5% to $1.65 billion, roughly 9.7% of total sales. Venclexta grew 11.6%, but Imbruvica plunged 29.4%. Etentamig could become the portfolio's next growth engine, but optimism is already expensive: the $260.445 share price stands 18.5% above the $219.78 GF Value™, raising the stakes for every clinical and regulatory milestone ahead.
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose Etentamig's dosing schedule and clinical profile may offer a differentiated treatment option for patients and providers Results support the potential of etentamig, a second-generation BCMA-directed T-cell engager, to enable treatment across a range of settings, including outpatient and community-based care , /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM). The study met its dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS). Full results will be presented in a plenary session at the 23rd International Myeloma Society Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
At the data cutoff, the Phase 3 CERVINO trial included 393 patients who had received a median of three prior lines of therapy. At the median follow-up of 11.4 months, etentamig demonstrated statistically significant and clinically meaningful efficacy with a manageable safety profile:
Significantly higher ORR with etentamig vs. SAT (74.0% [95% CI, 67.25–79.97] vs. 45.7% [95% CI, 38.59–52.91]; P<0.0001).2 Significantly improved PFS with etentamig vs. SAT (HR, 0.40; 95% CI, 0.29–0.54; P<0.0001). The PFS benefit was observed across all pre-specified subgroups evaluated.2 12-month overall survival (OS) was 87.9% for etentamig vs. 72.0% for SAT (HR, 0.48; 95% CI: 0.29–0.77; nominal P=0.0012); prespecified efficacy boundary for OS was not crossed at data cutoff.2 With a single step-up dose (SUD) and monthly (Q4W) dosing from initiation, etentamig demonstrated a potentially differentiated safety profile. Grade 3/4 infections occurred in 27.7% and 19.2% of patients receiving etentamig and SAT, respectively. Fewer grade 5 infections occurred with etentamig (1.5%) vs. SAT (3.1%). Among patients receiving a single step-up dose, the incidence of cytokine release syndrome (CRS) was low (28.3%) and predominantly grade 1 (23.9%) with no grade 3 or higher events reported. One patient experienced immune effector cell-associated neurotoxicity syndrome (ICANS) (0.9%, grade 1) with no grade 2 or higher events reported. Discontinuations related to treatment-emergent adverse events were low for etentamig vs. SAT (3.6% vs. 9.6%).2 This was the first planned efficacy interim analysis of the CERVINO study and, based on the significant benefit, the Independent Data Monitoring Committee (IDMC) recommended unblinding the study.
"In this heavily pre-treated, triple-class exposed patient population, etentamig delivered clinically meaningful improvements in progression-free survival and response rates, alongside a manageable safety profile characterized by predominantly low-grade cytokine release syndrome," said Dr. Peter Voorhees, Chief, Plasma Cell Disorders Division at Atrium Health Levine Cancer Institute and an investigator on the CERVINO study. "Together, with its administration and dosing schedule, these findings support etentamig's role as a BCMA-targeted bispecific treatment option for multiple myeloma patients, with the potential to provide access across a range of treatment settings beyond specialized treatment centers and into outpatient and community-based settings."
While BCMA-directed bispecific antibodies and CAR-T therapies have transformed multiple myeloma treatment, their adoption remains limited by adverse events such as CRS, neurotoxicity and infections, as well as the need for specialized monitoring and treatment infrastructure.3,4,5 These may limit access for many patients, particularly in community settings. As the disease relapses and available treatment options become increasingly limited, there remains a critical unmet need for additional therapy options across a range of treatment settings.3,4,5
"The Phase 3 CERVINO results support the scientific approach behind etentamig and demonstrate the value of designing therapies that address both the biology of multiple myeloma and the practical needs of patients and providers through a manageable safety profile, a convenient dosing schedule and the potential for treatment in outpatient and community-based care settings," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology, AbbVie. "These results underscore our confidence in etentamig and our broader multiple myeloma strategy, which explores complementary T-cell engagers, targeted small molecules and rational combinations designed to address distinct disease mechanisms and patient needs over time."
AbbVie plans to discuss the Phase 3 CERVINO results with global regulatory authorities to determine next steps for etentamig.
IMS Presentation Details:
Abstract Title
Date/Time
Session
CERVINO: Phase 3 Results of Etentamig
vs. Investigator's Choice of Standard
Available Therapies in Triple-Class
Exposed Relapsed or Refractory Multiple
Myeloma (RRMM)
Friday, September
25, 2026; 3 p.m.
PLENARY SESSION
Etentamig is an investigational asset and has not been approved for use by global regulatory authorities.
About the CERVINO Study1
CERVINO (NCT06158841) is a global, Phase 3, multicenter, randomized, open-label study evaluating etentamig versus investigator's choice of standard available therapies (SAT) in patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy, including exposure to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody. Patients were randomized 1:1 to receive etentamig administered once every four weeks (Q4W) or SAT, including carfilzomib plus dexamethasone, elotuzumab plus pomalidomide and dexamethasone, or selinexor plus bortezomib and dexamethasone. Etentamig was administered using an optimized dosing strategy that incorporates a single step-up dose followed by monthly (Q4W) dosing from initiation.
The dual primary endpoints of CERVINO are overall response rate (ORR) and progression-free survival (PFS). Key secondary endpoints include overall survival (OS), depth of response, measurable residual disease (MRD) negativity, disease symptoms and physical functioning.
About Etentamig
Etentamig is an investigational, second-generation BCMA x CD3 bispecific antibody T-cell engager designed to combine meaningful anti-myeloma activity with a differentiated treatment experience for patients. Etentamig is composed of a low-affinity CD3 binding domain, designed to reduce cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding enabling monthly (Q4W) dosing after a single step-up dose. Clinical correlations of these structure-activity relationships have not been fully established.6
BCMA is highly expressed on the surface of malignant plasma cells in multiple myeloma, making it an ideal target for therapy. BCMA plays a crucial role in the survival of myeloma cells by promoting their growth and inhibiting their apoptosis (programmed cell death).5
Several clinical studies are evaluating the potential of etentamig across diverse patient populations and treatment settings. To learn more about AbbVie's ongoing etentamig clinical trials, please visit clinicaltrials.gov.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
AbbVie. Data on file ABVRRTI83865. Voorhees P, Manteca V, Costa L, et al. "CERVINO: Phase 3 Results of Etentamig vs. Investigator's Choice of Standard Available Therapies in Triple-Class Exposed Relapsed or Refractory Multiple Myeloma (RRMM)." Abstract presented at International Myeloma Society Annual Meeting, 2026. Glasgow, Scotland. Hej-Ali S, Banwell K, Mohamed H, et al. Toxicities of CAR-T, bispecific antibodies, and antibody-drug conjugates in multiple myeloma: a practical approach to risk mitigation and management. Cancers (Basel). 2026;18(13):2083. doi:10.3390/cancers18132083. Benda M, Reimann P, Willenbacher W, et al. Infectious toxicities associated with bispecific antibodies and CAR-T cells in multiple myeloma: a systematic review. Ann Hematol. Published online June 18, 2026. doi:10.1007/s00277-026-07140-8. Graham T, Ackbarali T, Patel K, Richter J. Integrating bispecific antibodies into community myeloma care: challenges, insights, and educational impact. Blood. 2025;146(suppl 1):8134. doi:10.1182/blood-2025-8134. D'Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40(31):3576-3586. doi:10.1200/JCO.22.01504. SOURCE AbbVie
AbbVie (ABBV.N) said on Thursday its therapy for a type of blood cancer has improved patients' response rate to treatment and reduced the risk of disease progression or death, meeting the main goals of a late-stage trial.
As biosimilars chip away at sales of its arthritis treatment Humira, once its top-selling drug, the company is turning to acquisitions and other disease areas such as neuroscience and oncology to drive growth.
The therapy, etentamig, showed an objective response rate of 74% in patients with refractory multiple myeloma, higher than the 45.7% recorded by standard treatments chosen by the trial investigator. ORR is the percentage of patients in a clinical trial whose cancer shrinks or disappears after treatment.
Etentamig also increased survival without progression of the disease, and reduced the risk of the cancer worsening or death by 60% compared to other treatments in the 393-patient trial.
"For AbbVie, the data add credibility to oncology but do not change the investment debate," said Citi analyst Geoffrey Meacham. Commercial execution for newer drugs Skyrizi and Rinvoq remains paramount, while investors are increasingly focused on "whether additional transactions can deepen AbbVie's 2030s growth profile."
The trial included patients who received a median of three prior lines of treatment with relapsed or refractory multiple myeloma, a form of blood cancer that has returned after a period of remission or has stopped responding to treatment.
After 12 months, 87.9% of patients receiving etentamig were still alive, compared to 72% of patients receiving standard treatments.
Etentamig engages T-cells, which protect from infections and fight cancer, by targeting two proteins.
Meachem said etentamig looks most differentiated as an additional post-CAR-T cell therapy, rather than a replacement for Johnson & Johnson's (JNJ.N) Carvykti or Gilead's (GILD.O) anito-cel. "CAR-T offers deep responses and a treatment holiday, while etentamig offers immediate availability, monthly administration and broader treatment-center access."
Jericho Financial LLP bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 26,098 shares of the company’s stock, valued at approximately $6,567,000. AbbVie accounts for 3.4% of Jericho Financial LLP’s portfolio, making the stock its 15th largest position.
A number of other institutional investors have also added to or reduced their stakes in ABBV. State Street Corp boosted its position in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares in the last quarter. Bank of America Corp DE raised its position in shares of AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Norges Bank bought a new position in AbbVie in the 4th quarter worth about $5,865,055,000. Finally, Capital Research Global Investors boosted its stake in AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after purchasing an additional 177,370 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by insiders.
Analyst Upgrades and Downgrades Several research analysts have recently issued reports on ABBV shares. Royal Bank Of Canada upped their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Cantor Fitzgerald boosted their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Finally, Bank of America upped their price target on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95. View Our Latest Report on AbbVie
AbbVie Trading Up 0.6% NYSE ABBV opened at $261.50 on Thursday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The stock has a market cap of $462.02 billion, a price-to-earnings ratio of 73.87, a PEG ratio of 1.18 and a beta of 0.29. The company’s 50 day moving average is $254.23 and its two-hundred day moving average is $229.67.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the firm earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More Five stocks we like better than AbbVie Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Bank of Nova Scotia bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 337,881 shares of the company’s stock, valued at approximately $85,024,000.
A number of other large investors also recently made changes to their positions in ABBV. Norges Bank bought a new stake in AbbVie during the fourth quarter worth $5,865,055,000. Wellington Management Group LLP grew its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Capital World Investors grew its stake in AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Cardano Risk Management B.V. increased its position in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. 70.23% of the stock is owned by institutional investors.
Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
AbbVie Stock Performance ABBV stock opened at $261.50 on Thursday. The company has a market capitalization of $462.02 billion, a price-to-earnings ratio of 73.87, a PEG ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a fifty day moving average of $254.23 and a 200-day moving average of $229.67. AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts predict that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is 195.48%.
Analysts Set New Price Targets A number of equities analysts recently weighed in on ABBV shares. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Bank of America raised their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a research report on Thursday, August 13th. Cantor Fitzgerald boosted their target price on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.95.
Get Our Latest Report on ABBV
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More Five stocks we like better than AbbVie Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Barbara Oil Co. bought a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $5,033,000. AbbVie comprises about 1.7% of Barbara Oil Co.’s investment portfolio, making the stock its 17th biggest position.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Saranac Partners Ltd bought a new stake in shares of AbbVie in the 2nd quarter valued at about $10,354,000. Solstein Capital LLC bought a new stake in shares of AbbVie during the second quarter worth $279,000. Jericho Financial LLP acquired a new stake in shares of AbbVie in the 2nd quarter valued at about $6,567,000. Alpha Advisors LLC VA bought a new stake in shares of AbbVie in the second quarter valued at about $355,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of AbbVie during the second quarter worth about $189,104,000. Institutional investors own 70.23% of the company’s stock.
Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth ABBV has been the topic of several research reports. Citigroup boosted their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Wells Fargo & Company raised their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Cantor Fitzgerald lifted their price target on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.95. Check Out Our Latest Stock Report on AbbVie
AbbVie Stock Up 0.6% Shares of NYSE ABBV opened at $261.50 on Thursday. The business’s 50 day moving average price is $254.23 and its two-hundred day moving average price is $229.67. The company has a market cap of $462.02 billion, a PE ratio of 73.87, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is currently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More Five stocks we like better than AbbVie Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026.
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
"The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By combining Apogee's innovative science with AbbVie's proven development, regulatory and commercial capabilities, we aim to accelerate these programs and bring promising new treatment options to patients living with serious inflammatory and immunological diseases. We are excited to welcome the talented Apogee team to AbbVie and build on their important work."
Apogee's pipeline includes novel antibodies targeting multiple validated inflammatory pathways in large immunology and inflammation markets, including atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD).
Zumilokibart targets IL-13, a critical cytokine in type 2 inflammation, and a central driver of inflammatory diseases like AD and asthma. Specifically in AD, a majority of patients do not achieve simultaneous itch and skin improvement which represents an opportunity for the development of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing. In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment achieving significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control. These findings support its potential best-in-category profile, including strong efficacy and convenient dosing, in patients with AD. Longer-term data from the same trial also support maintenance regimens of either quarterly or twice a year dosing. The safety profile of zumilokibart is favorable and consistent with other medicines in its class, and the molecule has the potential to be evaluated in several additional inflammatory indications.
Beyond zumilokibart, Apogee has built a broader pipeline of novel antibodies targeting multiple validated inflammatory pathways. APG273 combines zumilokibart with APG333, an antibody that blocks thymic stromal lymphopoietin (TSLP), a signaling protein that acts as an early trigger of inflammation in the lungs. Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months after dosing. The Phase 1 data with APG333 and positive interim results from a Phase 1b study of zumilokibart in asthma, support the potential of the APG273 combination with quarterly or twice-yearly injections in asthma.
For additional background on the acquisition, please read the announcement press release here and view AbbVie's investor presentation here.
Financial Terms
AbbVie has acquired all outstanding Apogee common stock for $135.11 per share in cash, for a total equity value of approximately $10.9 billion. Apogee's common stock ceased trading on the NASDAQ stock exchange prior to market open on Sept. 3, 2026. AbbVie expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032.
Full-year 2026 Outlook
AbbVie is reaffirming its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07. This guidance includes a $0.14 per share dilutive impact related to the completed Apogee acquisition. AbbVie's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.
AbbVie is reaffirming its previously issued 2026 third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88. AbbVie's 2026 third-quarter adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred in the quarter, as both cannot be reliably forecasted.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs generally identify forward-looking statements. Statements in this news release that are forward-looking may include, but are not limited to, statements regarding AbbVie's 2026 full-year and third-quarter adjusted diluted EPS guidance, the anticipated benefits of AbbVie's completed acquisition of Apogee and AbbVie's ability to successfully integrate Apogee's operations, employees and pipeline; the expected impact of the acquisition on AbbVie's adjusted diluted earnings per share; and the anticipated development, regulatory progress and commercial potential of Apogee's pipeline assets. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the amount and timing of acquired IPR&D and milestones expense; the risk that the anticipated benefits and synergies of the Apogee acquisition may not be realized, or may take longer to realize than expected; risks and costs related to integrating Apogee's business, employees and pipeline into AbbVie, including the possibility that such integration may be more difficult, time-consuming or costly than anticipated; the risk that acquired in-process research and development assets, including zumilokibart (APG777) and APG273, may not demonstrate the anticipated success, safety or efficacy in ongoing or future clinical trials, and that positive interim or earlier-stage results may not be predictive of results in later-stage or larger clinical trials; the risk of unknown or contingent liabilities assumed in connection with the acquisition; challenges to intellectual property; competition from other products; difficulties inherent in the research and development process; adverse litigation or government action; changes to laws and regulations applicable to our industry; the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2026 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
, /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalization of minimally invasive procedures, and a decisive consumer shift away from surgery toward faster, lower-risk treatments. Now a powerful new catalyst has arrived from an unexpected direction, the explosion in GLP-1 weight-loss drugs, which is reshaping demand across the entire aesthetics landscape. Active companies from around the markets with current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Establishment Labs Holdings Inc. (NASDAQ: ESTA), Evolus, Inc. (NASDAQ: EOLS), InMode Ltd. (NASDAQ: INMD), and AbbVie Inc. (NYSE: ABBV).
The GLP-1 effect has become one of the most talked-about dynamics in the sector. As millions of patients lose weight rapidly on obesity drugs, many are left with facial volume loss and loose skin, a phenomenon the industry has come to call Ozempic® face, along with sagging elsewhere on the body. That has translated into rising demand for dermal fillers, body-contouring devices, skin-tightening treatments, and other procedures aimed at restoring volume and firmness. With the obesity-drug market projected to reach roughly US$100 billion in annual sales by 2030, the pool of patients who may seek aesthetic follow-up treatments is expanding faster than almost anyone anticipated. More background on the sector is available through Equity Insider.
Within that broad market, one of the most closely watched frontiers is regenerative aesthetics, the effort to move beyond simply filling or tightening tissue toward helping the body rebuild its own. Traditional dermal fillers and biostimulators address the symptoms of aging and volume loss; a newer wave of research is focused on biologic scaffolds and extracellular-matrix technologies that aim to support the body's own tissue regeneration. If that approach proves out, proponents argue it could open an entirely new category within aesthetics, one focused on restoration rather than temporary correction. It is an early-stage and still largely preclinical field, but it is drawing attention precisely because the aesthetics market has shown it will reward genuine innovation.
A Preclinical Company Positioned at the Regenerative Frontier
Conexeu Sciences Inc. (Nasdaq: CNXU) is a preclinical regenerative-tissue and medical-device company working at that regenerative frontier, developing collagen-based scaffold technology intended for applications across medical aesthetics, including facial rejuvenation and body restoration. Rather than competing head-on with established fillers or devices, the company is pursuing an extracellular-matrix approach designed to support the body's own tissue, positioning itself within the emerging regenerative-aesthetics theme rather than the mature injectable or biostimulator categories.
Points that place the company within the sector's current themes include:
A focus on regenerative, scaffold-based technology, aligning the company with the aesthetics industry's move toward restoration and tissue regeneration rather than temporary correction alone.A stated interest in body-restoration and facial-rejuvenation applications, areas of aesthetics seeing heightened demand amid the GLP-1-driven wave of post-weight-loss patients.A public listing on the Nasdaq under the symbol CNXU, giving public-market investors direct exposure to an early-stage regenerative-aesthetics story.A preclinical, investigational profile, meaning its technology is being advanced through development rather than being marketed or sold, which places it among the earliest-stage, highest-risk participants in the sector.As a preclinical company, Conexeu carries the risks that come with that status: its technology is investigational, has not received regulatory clearance or approval, generates no revenue, and must advance through extensive testing, regulatory review, and financing before it could reach the market, if it ever does. Those are substantial uncertainties, and they place the company at the speculative end of the aesthetics spectrum, in contrast to the commercial-stage companies that dominate the sector's revenue.
Continued... Read this and more news for Conexeu Sciences Inc. (Nasdaq: CNXU) at: https://equity-insider.com/pages/conexeu-cnxu/
In other industry developments and happenings in the market this week include:
Establishment Labs Holdings Inc. (Nasdaq: ESTA)
Establishment Labs is a medical-technology company focused on breast and body aesthetics and reconstruction, best known for its Motiva® family of implants and a growing minimally invasive product line. Its focus on breast and body applications makes it one of the more relevant reference points for the tissue-and-contouring end of the aesthetics market that regenerative approaches are also targeting.
Establishment Labs has been among the aesthetics names explicitly cited as positioned to benefit from patients seeking body and skin treatments following GLP-1-driven weight loss, and it continues to expand internationally and in the United States. It is referenced only as market and sector context, a far larger and commercial-stage company compared with a preclinical developer, and its results are not indicative of the featured company's prospects.
Evolus, Inc. (Nasdaq: EOLS)
Evolus is a performance-beauty company built around its flagship neurotoxin Jeuveau®, which has been described as one of the fastest-growing botulinum toxin products in the U.S. aesthetics market, and it has been expanding into dermal fillers to broaden its portfolio. It represents the injectable end of the aesthetics market, the established category that regenerative approaches are positioned alongside rather than within.
Evolus has guided to continued double-digit revenue growth and has pointed to rising filler demand, including from patients addressing facial volume loss after rapid weight loss, as a tailwind. It is referenced solely as sector context, a commercial-stage company at a completely different stage from the featured company, and not as a peer or financial comparable.
InMode Ltd. (Nasdaq: INMD)
InMode designs and markets energy-based medical devices for aesthetic and medical treatments, with a portfolio spanning body contouring, skin tightening, and minimally invasive procedures. Its device-based approach to tightening and contouring addresses the same post-weight-loss skin-laxity demand that is reshaping the sector, making it a useful reference for the energy-device category.
InMode has cited GLP-1-related demand for skin-tightening and body-contouring treatments as a factor in its business, while contending with a more cautious capital-equipment spending environment among providers. It is referenced only as market and sector context, a far larger and profitable commercial-stage company compared with a preclinical developer, whose results are not indicative of the featured company's prospects.
AbbVie Inc. (NYSE: ABBV)
AbbVie is a global biopharmaceutical company whose Allergan Aesthetics division is the dominant force in medical aesthetics, home to Botox® Cosmetic, the Juvederm® filler family, and CoolSculpting® body contouring. As the sector's largest and most established player, with aesthetic product sales measured in the billions, it defines the commercial landscape any new entrant is measured against.
AbbVie has continued to innovate across its aesthetics portfolio, including recent regulatory milestones for new injectable products, and remains the reference point for scale and physician confidence in the category. It is referenced purely as market and sector context, an enormously larger and diversified company operating at a vastly different scale from the featured company, and not as a comparable.
Why the Aesthetics Boom Reaches All the Way to the Preclinical Frontier
What connects these companies is a single market reality: aesthetic medicine is growing quickly, its demand base is broadening thanks to demographic and now pharmacological tailwinds, and the sector has repeatedly rewarded innovation that gives patients better, longer-lasting, or more natural results. That environment pulls capital and attention across the full spectrum, from the large-cap incumbents and commercial-stage device and injectable makers that generate the sector's revenue today, to the early-stage and preclinical companies pursuing the regenerative technologies that could define its next category. The GLP-1 wave, the shift toward minimally invasive procedures, and the search for regenerative solutions all point in the same direction, even as the sector spans wildly different levels of maturity and risk.
For preclinical participants, that backdrop is opportunity and risk in equal measure. Early-stage medical-device and biologic companies are highly speculative, face long and uncertain regulatory pathways, generate no revenue, depend on continued financing, and may never bring a product to market. This commentary describes a sector and the companies active within it, and is not a prediction about any company's stock or a recommendation of any kind. But with aesthetics demand accelerating and the industry actively searching for its next category, the regenerative frontier is a corner of the market worth following through Equity Insider as it develops.
Track the Signals Before the Crowd
The best positioning happens before the crowd catches on. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev.
Equity Insider | [email protected]
DISCLAIMER
Nothing in this publication should be considered personalized financial advice. We are not licensed under securities laws to address your particular financial situation, and no communication from us should be deemed personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are neither licensed nor qualified to provide investment advice. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform their own research and due diligence and to consult a licensed financial professional before considering any level of investing in stocks.
This article is being distributed by Equity Insider, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. MEL has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). MEL also expects to receive further compensation in the future as part of an ongoing digital media effort to increase visibility for the company. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision. No further notice will be given, but let this disclaimer serve as notice that all material, including this article, has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG.
MEL and its owner(s) and operator(s) do not own any shares of Conexeu Sciences Inc., but reserve the right to buy and sell shares of Conexeu Sciences Inc. at any time without any further notice commencing immediately and ongoing, in the open market, through private placements, and/or through other investment vehicles. There may also be third parties who hold shares of Conexeu Sciences Inc. and may liquidate their shares, which could have a negative effect on the price of the stock.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This document is governed by the laws of Ireland.
References to Establishment Labs Holdings Inc., Evolus, Inc., InMode Ltd. and AbbVie Inc. are provided solely as market and sector context. Those companies are not peers, competitors, or financial comparables of Conexeu Sciences Inc. They are at materially different stages of development and scale, are commercial-stage companies with marketed products and revenue whereas the profiled company is preclinical with none, and their products, revenue, and share performance are not indicative of Conexeu Sciences Inc.'s prospects. No partnership, affiliation, sponsorship, or endorsement is implied, and none of them has any involvement in Conexeu Sciences Inc., this article, or its distribution. Market size figures cited are third-party estimates and projections that vary materially by source and are not presented as addressable revenue for any company named.
Readers are cautioned that investing in preclinical and development-stage medical-device and biologic companies is highly speculative and carries a high degree of risk. Conexeu Sciences Inc. is a preclinical company: its technology is investigational, has not been cleared or approved by the U.S. Food and Drug Administration or any other regulator, generates no revenue, and must advance through extensive preclinical and clinical testing, regulatory review, and additional financing before it could potentially reach commercialization, which it may never achieve. Statements regarding its technology, applications, and future plans are the company's expectations and disclosures, not achieved results, and are sensitive to regulatory, clinical, financing, competitive, and commercialization risks. Please refer to the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov for the assumptions and risk factors associated with its disclosure.
Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies (including the development and potential applications of the company's regenerative-tissue and scaffold technology) and are generally preceded by words such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "plans", "potential" or similar expressions. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected, including regulatory, clinical, financing, competitive, and commercialization risks, and other risks disclosed in the company's filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made as of the date hereof, and Equity Insider undertakes no obligation to update them except as required by law.
Trademarks
Motiva® is a registered trademark of Establishment Labs Holdings Inc. Jeuveau® is a registered trademark of Evolus, Inc. Botox® Cosmetic and Juvederm® are registered trademarks of AbbVie Inc. / Allergan Aesthetics. CoolSculpting® is a registered trademark of AbbVie Inc. Ozempic® is a registered trademark of Novo Nordisk A/S. All third-party trademarks, trade names, and product names referenced in this article are the property of their respective owners and are used for identification and informational purposes only. Their use does not imply any affiliation with, endorsement by, or sponsorship of Conexeu Sciences Inc. or the publisher.
Article Sources:
[1] Company disclosures of Conexeu Sciences Inc. regarding its regenerative-tissue and collagen-based scaffold technology, aesthetics applications, and Nasdaq listing, at www.conexeu.com.
[2] Medical aesthetics market size and growth estimates (approximately US$22–$23 billion in 2026, projected to approximately US$40 billion by 2031 at a CAGR near 12 percent) are drawn from third-party market-research publications, including Grand View Research, Fortune Business Insights, and Mordor Intelligence. Figures vary materially by source, definition, and methodology.
[3] The projection that the global obesity / GLP-1 drug market could reach roughly US$100 billion in annual sales by 2030 reflects third-party analyst and market-research estimates, including published forecasts from Goldman Sachs Research and industry analysts. Such projections are estimates only and are subject to change.
[4] Public disclosures and market data of the referenced companies (Establishment Labs Holdings, Evolus, InMode, and AbbVie), and industry reporting on the GLP-1 and post-weight-loss demand dynamic and injectable, device, biostimulator, and regenerative aesthetics trends, as cited in the body of this article.
View original content to download multimedia:https://www.prnewswire.com/news-releases/a-wave-of-weight-loss-drugs-is-quietly-creating-a-multi-billion-dollar-opportunity-that-aesthetic-medicine-is-racing-to-capture-302866509.html
Advisors Capital Management LLC bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 505,318 shares of the company’s stock, valued at approximately $127,158,000. AbbVie makes up about 1.3% of Advisors Capital Management LLC’s portfolio, making the stock its 14th largest holding.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Cannon Wealth Management Services LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth $259,000. MJP Associates Inc. ADV purchased a new stake in shares of AbbVie during the second quarter valued at about $2,051,000. PCM Encore LLC acquired a new stake in AbbVie in the second quarter valued at approximately $2,763,000. Trillium Asset Management LLC acquired a new stake in shares of AbbVie in the 2nd quarter worth $715,000. Finally, Altman Advisors Inc. purchased a new stake in shares of AbbVie during the second quarter worth about $2,449,000. Institutional investors own 70.23% of the company’s stock.
Analyst Ratings Changes A number of research analysts have recently weighed in on the company. Guggenheim increased their price objective on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. HSBC reissued a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a report on Monday, July 6th. Citigroup raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Morgan Stanley restated an “overweight” rating and issued a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $275.95.
View Our Latest Stock Report on ABBV Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn’s disease. The filing, supported by Phase 3 AFFIRM data, could broaden Skyrizi’s commercial opportunity and help offset longer-term concerns about AbbVie’s product portfolio. Is AbbVie Undervalued As It Expands Skyrizi In Crohns Disease? Positive Sentiment: Analysts remain broadly optimistic about ABBV’s outlook despite the stock’s reported underperformance versus healthcare peers over the past year. The aging population is also viewed as a long-term demand driver for AbbVie’s immunology treatments. How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. Investors may look for updates on Skyrizi, Rinvoq and the company’s earnings outlook, but no new financial information was provided in the announcement. AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference Neutral Sentiment: Trading has been relatively steady as investors await the next earnings update. Recent results provide a supportive backdrop: AbbVie previously exceeded quarterly EPS and revenue expectations, with revenue up year over year. AbbVie Stock Holds Steady as Investors Await the Next Earnings Update Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate for AbbVie, creating a modest headwind for the stock and highlighting the risk that expectations may be difficult to exceed. Negative Sentiment: Recent institutional activity was mixed, with Burke & Herbert Bank & Trust selling shares while another manager initiated a position. These 13F changes are historical and have limited near-term significance, but the sale may add slight negative sentiment. Burke and Herbert Bank Sells AbbVie Shares AbbVie Stock Up 0.6% NYSE:ABBV opened at $256.95 on Tuesday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The stock’s 50-day moving average price is $253.20 and its 200-day moving average price is $229.16. The stock has a market capitalization of $453.98 billion, a PE ratio of 72.58, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30.
AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is currently 195.48%.
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories Five stocks we like better than AbbVie Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Beckerman Institutional LLC bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,028 shares of the company’s stock, valued at approximately $510,000.
Several other hedge funds have also recently modified their holdings of ABBV. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at about $28,000. Imprint Wealth LLC raised its holdings in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in AbbVie during the fourth quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID lifted its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.
Analyst Upgrades and Downgrades A number of equities analysts recently issued reports on ABBV shares. Wells Fargo & Company raised their price objective on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Barclays lifted their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $275.95.
Read Our Latest Analysis on AbbVie AbbVie Price Performance NYSE:ABBV opened at $256.95 on Tuesday. The company has a market cap of $453.98 billion, a price-to-earnings ratio of 72.58, a PEG ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The stock’s 50 day simple moving average is $253.20 and its two-hundred day simple moving average is $229.16.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
Trending Headlines about AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for a subcutaneous induction regimen of Skyrizi in adults with moderately to severely active Crohn’s disease. The filing, supported by Phase 3 AFFIRM data, could broaden Skyrizi’s commercial opportunity and help offset longer-term concerns about AbbVie’s product portfolio. Is AbbVie Undervalued As It Expands Skyrizi In Crohns Disease? Positive Sentiment: Analysts remain broadly optimistic about ABBV’s outlook despite the stock’s reported underperformance versus healthcare peers over the past year. The aging population is also viewed as a long-term demand driver for AbbVie’s immunology treatments. How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks Neutral Sentiment: AbbVie will present at the Wells Fargo Healthcare Conference on September 9. Investors may look for updates on Skyrizi, Rinvoq and the company’s earnings outlook, but no new financial information was provided in the announcement. AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference Neutral Sentiment: Trading has been relatively steady as investors await the next earnings update. Recent results provide a supportive backdrop: AbbVie previously exceeded quarterly EPS and revenue expectations, with revenue up year over year. AbbVie Stock Holds Steady as Investors Await the Next Earnings Update Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate for AbbVie, creating a modest headwind for the stock and highlighting the risk that expectations may be difficult to exceed. Negative Sentiment: Recent institutional activity was mixed, with Burke & Herbert Bank & Trust selling shares while another manager initiated a position. These 13F changes are historical and have limited near-term significance, but the sale may add slight negative sentiment. Burke and Herbert Bank Sells AbbVie Shares Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is owned by insiders.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading Five stocks we like better than AbbVie Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks1 SkinMedica® also introduces HA5® Hydra Collagen Facial Mist for easy, on-the-go hydration , /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), expands SkinMedica's portfolio of regenerative skincare products with the launch of Barrier Calming Cream. The restorative moisturizer is designed to soothe skin while helping restore and fortify the delicate skin barrier.
SkinMedica® Introduces Barrier Calming Cream and HA⁵® Hydra Collagen Facial Mist with Vegan Collagen
SkinMedica® Introduces Barrier Calming Cream and HA⁵® Hydra Collagen Facial Mist with Vegan Collagen Protecting the skin barrier is the foundation of regenerative skincare. Beyond targeting visible concerns, regenerative skincare focuses on supporting the skin's natural renewal process. Seventy percent of skincare consumers in the U.S. say they are more focused on protecting their skin barrier today than they were a year earlier.2
"SkinMedica was a pioneer in regenerative skincare long before it became one of the industry's fastest-growing movements," said Nicole Mowad-Nassar, senior vice president, AbbVie and president, Global Allergan Aesthetics. "With the launch of Barrier Calming Cream, we're continuing to advance our portfolio of science-backed solutions that meet consumers' growing focus on skin barrier health and support healthier-looking skin over time."
The Barrier Calming Cream is powered by Calcium Strengthening Complex and Botanical Calming Complex. Together, these advanced complexes provide:
Barrier restoration: Known for its role in bone health, calcium also helps rebalance the skin barrier, promoting resilience when the skin is stressed. Instant calm: Mondo grass root in the Botanical Calming Complex helps calm visible redness and supports tolerance of harsh ingredients. Lasting hydration: The formula helps seal in moisture by replenishing natural lipids. In clinical testing, Barrier Calming Cream improved skin barrier support and reduced skin dryness by 30% after just two weeks.1 "The skin barrier is your body's first line of defense against external stressors. When the barrier is compromised, skin can become dry and sensitive, and even the most powerful ingredients can't perform the way they are intended," said Prithwiraj Maitra, Ph.D., vice president, global skincare research and development, Allergan Aesthetics. "The Barrier Calming Cream is clinically proven to help restore the skin barrier and support skin's retinol tolerance."3
SkinMedica® also recently launched HA5® Hydra Collagen Facial Mist with Vegan Collagen. The ultra-fine mist is designed to be used over skincare, makeup, and sunscreen, without leaving behind residue for a refreshing boost of hydration between morning and evening skincare routines.
The formula features five forms of hyaluronic acid and vegan Hydra Collagen and is designed to support both instant and lasting hydration. In clinical testing, the mist immediately increased skin hydration levels by 31% with one application and improved skin dryness by 62%.3
SkinMedica® Barrier Calming Cream ($140) and SkinMedica® HA5® Hydra Collagen Facial Mist with Vegan Collagen ($58) are available at SkinMedica.com and through a network of licensed physicians and medically supervised spas. Follow @SkinMedica on Instagram for more information.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skincare, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
SkinMedica® Important Information
Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.
For more information, please talk to your provider or visit SkinMedica.com and DiamondGlow.com. To report an adverse reaction, please call Allergan at 1-800-433-8871.
August Group Capital Ltd purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,461 shares of the company’s stock, valued at approximately $871,000. AbbVie comprises about 1.0% of August Group Capital Ltd’s holdings, making the stock its 27th largest holding.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ranch Capital Advisors Inc. lifted its holdings in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of AbbVie during the second quarter worth $23,557,000. Wedge Capital Management L L P NC boosted its position in shares of AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, Mission Wealth Management LP grew its stake in shares of AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after acquiring an additional 37,531 shares in the last quarter. 70.23% of the stock is owned by institutional investors.
Insider Buying and Selling In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.
AbbVie Trading Up 0.2% ABBV opened at $256.08 on Monday. The company’s 50 day moving average is $252.66 and its 200-day moving average is $228.91. The company has a market cap of $452.44 billion, a P/E ratio of 72.34, a PEG ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.
AbbVie Announces Dividend The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.
Wall Street Analysts Forecast Growth A number of research firms have recently weighed in on ABBV. HSBC reiterated a “buy” rating and issued a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Royal Bank Of Canada boosted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Finally, Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $275.95.
View Our Latest Stock Analysis on ABBV
Key AbbVie News Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles Five stocks we like better than AbbVie Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
AssuredPartners Investment Advisors LLC purchased a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,321 shares of the company’s stock, valued at approximately $6,372,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie during the 4th quarter worth about $28,000. Imprint Wealth LLC raised its position in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, Marquette Asset Management LLC grew its stake in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.
AbbVie Stock Performance NYSE ABBV opened at $256.08 on Monday. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The company’s 50 day moving average price is $252.66 and its 200 day moving average price is $228.91. The firm has a market capitalization of $452.44 billion, a price-to-earnings ratio of 72.34, a PEG ratio of 0.85 and a beta of 0.30. AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the business earned $2.97 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.
AbbVie Announces Dividend The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.
Analyst Ratings Changes Several research firms have recently issued reports on ABBV. Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. UBS Group lifted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Citigroup increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.
Get Our Latest Stock Analysis on AbbVie
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Recommended Stories Five stocks we like better than AbbVie Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Asahi Life Asset Management CO. LTD. bought a new position in AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,363 shares of the company’s stock, valued at approximately $1,098,000.
A number of other institutional investors have also recently bought and sold shares of the stock. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $28,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the period. IFC & Insurance Marketing Inc. purchased a new position in AbbVie in the fourth quarter valued at approximately $31,000. Finally, Abound Financial LLC acquired a new position in AbbVie during the fourth quarter valued at approximately $32,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
AbbVie Stock Up 0.2% Shares of AbbVie stock opened at $256.08 on Monday. The firm has a market cap of $452.44 billion, a P/E ratio of 72.34, a P/E/G ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The business has a 50-day moving average price of $252.66 and a 200 day moving average price of $228.91.
AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year. AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is presently 195.48%.
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades A number of brokerages have recently commented on ABBV. BNP Paribas Exane raised their target price on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Finally, Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $275.95.
Read Our Latest Research Report on AbbVie
AbbVie Company Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Further Reading Five stocks we like better than AbbVie Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
DCF Advisers LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,750 shares of the company’s stock, valued at approximately $2,705,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in ABBV. one8zero8 LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $2,370,000. Kentucky Farm Bureau Mutual Insurance Co purchased a new stake in AbbVie in the 2nd quarter valued at $4,278,000. Addison Advisors LLC bought a new position in AbbVie during the 2nd quarter valued at $203,000. Mmbg Investment Advisors CO. bought a new position in AbbVie during the 2nd quarter valued at $4,307,000. Finally, West Family Investments Inc. purchased a new position in AbbVie during the 2nd quarter worth $999,000. Institutional investors and hedge funds own 70.23% of the company’s stock.
Wall Street Analysts Forecast Growth ABBV has been the subject of several analyst reports. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. UBS Group upped their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. BMO Capital Markets increased their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.95.
Check Out Our Latest Stock Report on AbbVie Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy? Insider Buying and Selling at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by insiders.
AbbVie Stock Performance ABBV opened at $256.08 on Monday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a 50-day moving average of $252.66 and a 200 day moving average of $228.91. The firm has a market cap of $452.44 billion, a P/E ratio of 72.34, a PEG ratio of 0.85 and a beta of 0.30.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.
AbbVie Profile (Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles Five stocks we like better than AbbVie Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
